Mothers and Babies (MB) is a program that promotes healthy mood management by teaching pregnant women and new moms how to effectively respond to stress in their lives through increasing the frequency of thoughts and behaviors that lead to positive mood states. Designed as a perinatal depression prevention, the Mothers and Babies targets three specific risk factors: limited social support, lack of pleasant activities, and harmful thought patterns. Mothers and Babies offers a “toolkit” of approaches for women to observe their mood, note factors affecting their mood, and make changes in their daily lives to impact these areas. Based on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation, the Mothers and Babies Course is designed to be delivered by clinic- or community-based providers from a variety of educational and professional backgrounds, and can be delivered as a group intervention or as a one-on-one intervention in various settings where pregnant women access services (e.g. prenatal clinics, home visiting programs, WIC programs, County Health Departments, etc.).
This colorful and easy-to-read patient brochure can be downloaded or ordered for free from the CDC. It discusses the effects of STDs on pregnancy and the importance of being tested for STDs before and/or during pregnancy. It reviews the preventive measures women can take to avoid contracting an STD before or during pregnancy and emphasizes the importance of being treated during pregnancy if required.
The incidence of syphilis in American women doubled between 2012 and 2016, and the incidence of congenital syphilis rose concomitantly. Congenital syphilis can lead to stillbirth, neonatal death, and lasting effects such as bone deformities and neurologic impairment in the newborn. Because of this, the USPSTF has reiterated its guidance that all pregnant women be tested for syphilis at their first prenatal visit. They also point out that many organizations recommend repeat testing of high-risk women in the third trimester and at delivery.
This patient handout in the form of questions and answers is designed to inform pregnant women and women planning a pregnancy about the risks of HIV infection during pregnancy. It covers the basics of HIV infection, its potential risks to pregnant women and their babies, and how these risks can be minimized with early diagnosis, certain preventive measures, and HIV treatment.
This recently revised document discusses the rationale and recommendations for “opt-out” HIV testing in pregnancy. It explains how test results can be used to guide treatment for HIV in pregnancy in order to optimize outcomes for both mother and baby.
The Alliance for Innovation on Maternal Health (AIM) is a national data-driven maternal safety and quality improvement initiative based on proven implementation approaches to improving maternal safety and outcomes in the U.S. The AIM supported safety bundles are collections of evidence based protocols and best practices for improving safety in maternity care, and handling obstetric complications and emergencies in hospital and outpatient settings. AIM provides implementation and data support for each AIM supported patient safety bundle.
This toolkit provides a foundation, framework and resources for advancing maternal health in the U.S. as a human rights issue. It provides a research overview of maternal morbidity and mortality, focusing on trends, health disparities and inequities. Based on the deliberations of a cross-sectoral convening of stakeholders it offers a state policy framework for upholding the right to safe and respectful maternal health care, which offers recommendations in six key areas: improving access to reproductive health care, improving quality of maternal health care, ensuring acceptability of maternal health care for women most at risk, ensuring widespread availability of maternal health services, ensuring non-discrimination in access to care and social determinants of health, and fostering accountability to human rights standards for maternal health care.
This guide provides information and resources for family members and friends on specific ways to support pregnant women with opioid use disorders, and help them to get the prenatal care, substance use treatment and other supports they need during pregnancy and postpartum.
This guide is intended to support the efforts of states, tribes, and local communities in addressing the needs of pregnant women with opioid use disorders and their infants and families, through a coordinated, multi-sytem approach. The guide is designed to assist healthcare providers, SUD treatment providers, child welfare programs and judicial systems to improve their collaborative practice, and to offer information about additional resources that will strengthen their capacity to provide coordinated, best-practice care and services Collaborative planning and implementation of services that reflect best practices for treating opioid use disorders during pregnancy are yielding promising results in communities across the country. .
This interactive toolkit allows users to learn from participants in the Collaborative Improvement and Innovation Network to Reduce Infant Mortality (Infant Mortality CoIIN). The resource is organized by topics from the initiative, including social determinants of health, pre- and interconception care, risk-appropriate prenatal care, pre- and early- term births, smoking cessation, and safe sleep practices. It features change ideas, model programs, videos, and key insights from teams who are working to reduce infant mortality throughout the country.
The Healthy Start EPIC Center is operated by the National Institute for Children's Health Quality. This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number 1 UF5MC327500100 titled Supporting Healthy Start Performance Project. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.
